Clinical trials: Motor Fluctuations
Parkinson Disease (PD), Parkinson's Disease
Real-world Patient Experiences With Inbrija®
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing.
- Conditions
- Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
- Trial name
- INHALE-PD (NCT07797790)
- Testing
- Levodopa inhalation powder
- Where
- 2 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Merz Therapeutics GmbH
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Advanced Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
- Trial name
- NCT00407095
- Testing
- Pardoprunox
- Where
- 87 sites in United States, Albania and 11 more
- Volunteers
- 140 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be…
- Trial name
- NCT01229332
- Testing
- Saline, Carbidopa
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- NeuroDerm Ltd.
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
- Trial name
- NCT07422675
- Testing
- SER-252 (PEOZ-apomorphine), enFuse
- Where
- 6 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Serina Therapeutics
Parkinson's Disease
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2…
- Trial name
- ND0612/003 (NCT01883505)
- Testing
- ND0612, Entacapone
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NeuroDerm Ltd.
Parkinson Disease
OpicApone Sleep dISorder
The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's…
- Trial name
- OASIS (NCT04986995)
- Testing
- Opicapone
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Parkinson's Disease (PD) is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons.
- Trial name
- NCT00865579
- Testing
- Safinamide
- Where
- Romania
- Volunteers
- 964 people
- Sponsor
- Newron Pharmaceuticals SPA
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson's Disease
Parkinson's KinetiGraph as Tool for DBS Eligibility Assessment
The purpose of the study is to investigate the feasibility of using the commercially available Parkinson's KinetiGraph Data Logger (PKG) to quantitatively assess motor fluctuations in Parkinson's Disease (PD) patients.
- Trial name
- KITE (NCT02509325)
- Testing
- Parkinson's Kinetigraph
- Where
- 2 sites in France, Germany
- Volunteers
- 38 people
- Sponsor
- MedtronicNeuro
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00660387
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 14 sites in United States, New Zealand
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Parkinson's Disease
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment…
- Trial name
- NCT00660673
- Testing
- Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 262 people
- Sponsor
- AbbVie
Idiopathic Parkinson's Disease
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- SPAN-PD™ (NCT02240030)
- Testing
- CVT-301 Low Dose, CVT-301 High Dose
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 351 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease, Motor Disorder
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
- Trial name
- NCT03608371
- Testing
- BTRX-246040
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Parkinson's Disease With Wearing-off Motor Fluctuations
Efficacy and Safety of Opicapone in Clinical Practice
The purpose of this study is to evaluate the change in subject's condition according to the Investigator's Global Assessment of Change after three months of treatment with 50 mg opicapone once daily in a heterogeneous patient…
- Trial name
- OPTIPARK (NCT02847442)
- Testing
- BIA 9-1067, levodopa/dopa decarboxylase inhibitor
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after administration of XP21279/Carbidopa and Sinemet and to…
- Trial name
- NCT01171313
- Testing
- XP21279 and carbidopa (experimental), Sinemet (comparator)
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- XenoPort, Inc.
Parkinson's Disease
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical…
- Trial name
- TOLEDO (NCT02006121)
- Testing
- Apomorphine hydrochloride
- Where
- 20 sites in Austria, Denmark and 5 more
- Volunteers
- 107 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Parkinson Disease
REal-life ON PARKinson's - ITaly (REONPARK-IT)
The present study aims to evaluate the effectiveness and safety of opicapone in a real-world setting at centers for Parkinson's disease located in Italy.
- Trial name
- NCT07403799
- Testing
- Opicapone 50 mg
- Where
- 20 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential…
- Trial name
- NCT02224664
- Testing
- PF-06649751
- Where
- 17 sites in United States, Belgium
- Volunteers
- 50 people
- Sponsor
- Pfizer